Eli Lilly and Company $LLY Holdings Increased by Focus Partners Wealth

Focus Partners Wealth grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 35.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 222,242 shares of the company’s stock after buying an additional 58,320 shares during the quarter. Focus Partners Wealth’s holdings in Eli Lilly and Company were worth $237,498,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Fort Point Capital Partners LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $376,000. Fortitude Advisory Group L.L.C. raised its position in shares of Eli Lilly and Company by 15.7% during the 4th quarter. Fortitude Advisory Group L.L.C. now owns 941 shares of the company’s stock worth $1,012,000 after buying an additional 128 shares in the last quarter. Glen Eagle Advisors LLC raised its position in shares of Eli Lilly and Company by 1.5% during the 4th quarter. Glen Eagle Advisors LLC now owns 3,691 shares of the company’s stock worth $3,967,000 after buying an additional 56 shares in the last quarter. KCM Investment Advisors LLC raised its position in shares of Eli Lilly and Company by 0.4% during the 4th quarter. KCM Investment Advisors LLC now owns 25,026 shares of the company’s stock worth $26,895,000 after buying an additional 90 shares in the last quarter. Finally, Knollwood Investment Advisory LLC raised its position in shares of Eli Lilly and Company by 0.5% during the 4th quarter. Knollwood Investment Advisory LLC now owns 13,783 shares of the company’s stock worth $14,812,000 after buying an additional 66 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts and research notes continue to turn more upbeat on Eli Lilly’s earnings outlook, with Erste Group lifting FY2026 and FY2027 EPS estimates and Goldman Sachs reiterating a buy rating on the back of an encouraging obesity-treatment pipeline. Goldman Sachs Maintains a Buy Rating on Eli Lilly (LLY), Cites Encouraging Obesity Treatment Pipeline
• Positive Sentiment: Eli Lilly’s strong growth story is still resonating with investors: recent coverage says the stock is in a buy zone, institutional funds are adding shares, and the company remains a leader in the GLP-1 obesity market after a big earnings beat and raised guidance. Eli Lilly Stock Hits Buy Zone As Earnings Soar 156%. Funds Are Loading Up.
• Positive Sentiment: The company also added a new growth angle by expanding its chronic pain pipeline, including new Phase 2 trials in osteoarthritis and chronic low back pain, which could broaden Lilly’s long-term revenue base beyond obesity and diabetes. Eli Lilly Expands Chronic Pain Pipeline With New Osteoarthritis Trial
• Positive Sentiment: FDA progress for Ebglyss, including an easier once-every-eight-weeks maintenance regimen, adds another commercial catalyst and supports Lilly’s push to diversify into dermatology. FDA Ebglyss Decision Adds New Thread To Eli Lilly Growth Story
• Neutral Sentiment: Lilly also unveiled an AI partnership with Abridge, aimed at speeding drug development, trial enrollment and research; that is strategically positive, but it is a longer-term story than a near-term earnings driver. Eli Lilly’s Abridge Bet Links Healthcare AI To Valuation And Growth
• Negative Sentiment: A key overhang is growing concern that some employers may reduce or drop coverage for GLP-1 weight-loss drugs in 2027, which could pressure demand and reimbursement for Lilly’s obesity franchise. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases 2026-06-11

Analysts Set New Price Targets

A number of analysts have commented on the stock. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 8th. Royal Bank Of Canada restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Morgan Stanley reiterated an “overweight” rating on shares of Eli Lilly and Company in a report on Friday, June 5th. HSBC downgraded shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and dropped their target price for the stock from $1,070.00 to $850.00 in a report on Tuesday, March 17th. Finally, Rothschild & Co Redburn boosted their target price on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $1,227.74.

Eli Lilly and Company Stock Up 0.4%

NYSE LLY opened at $1,137.01 on Monday. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The company’s 50 day simple moving average is $998.47 and its 200 day simple moving average is $1,016.36. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,182.73. The company has a market capitalization of $1.07 trillion, a P/E ratio of 40.39, a PEG ratio of 1.24 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same period last year, the firm posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th were given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.